In June 2020, a biopharmaceutical company agreed to acquire a gene therapy research company’s novel late-stage gene therapy candidate for hemophilia B patients. In the FTC investigation that followed, Dr. Smith led a Brattle team in work demonstrating that little competition between the biopharmaceutical company’s gene therapy products would be lost through the proposed transaction. This work included a gene therapy adoption analysis that demonstrated the biopharmaceutical company’s incentive to market its products without delay. The transaction was cleared in April 2021.

Experts Involved